Elective Cardiac Surgery
10
2
2
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
10%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery
Parasternal Blockade and Serum Lactate in Cardiac Surgery
Pleiades Safety and Feasibility Study
Influence of Corticoids on Renal Function in Cardiac Surgery
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
Acceptable Range of Inspiratory Effort During Mechanical Ventilation
Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery
Microcirculation of the Thenar Eminence
Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery